GPCR Structure Therapeutics Inc. American Depositary Shares

$18.80

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 8/19/2025

About Structure Therapeutics Inc. American Depositary Shares

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company is headquartered in South San Francisco, California.

Website: https://structuretx.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1888886
Address
601 GATEWAY BLVD., SUITE 900, SOUTH SAN FRANCISCO, CA, UNITED STATES
Valuation
Market Cap
$1.25B
P/E Ratio
nan
PEG Ratio
nan
Price to Book
1.44
Performance
EPS
$-2.34
Dividend Yield
—
Profit Margin
0.00%
ROE
-18.60%
Technicals
50D MA
$20.85
200D MA
$31.96
52W High
$62.74
52W Low
$13.22
Fundamentals
Shares Outstanding
57M
Target Price
$80.15
Beta
-1.46

GPCR EPS Estimates vs Actual

● Estimated
● Actual

GPCR News & Sentiment

Aug 19, 2025 • Benzinga NEUTRAL
New Obesity Drugs May See Premium Pricing Undermined By Underwhelming Data - Eli Lilly ( NYSE:LLY )
Novo's pill requires ~75 times more active ingredient per week than Wegovy injections. Lilly has $808.5 million in orforglipron inventory ahead of its planned 2026 launch. Get the exact trades and sectors to target before August's biggest earnings-driven market moves. Details here →
Aug 17, 2025 • Motley Fool SOMEWHAT-BULLISH
This Healthcare Stock's Bad News Could Create a $10 Billion Opportunity for Competitors
The drugmaker's recent dip could also be a buying opportunity.
Aug 07, 2025 • Benzinga NEUTRAL
Why Are Weight-Loss Stocks Gaining Thursday? - Viking Therapeutics ( NASDAQ:VKTX ) , Novo Nordisk ( NYSE:NVO ) , Structure Therapeutics ( NASDAQ:GPCR ) , Terns Pharma ( NASDAQ:TERN )
Eli Lilly's orforglipron showed 12.4% weight loss vs. 0.9% with placebo, below the 15% expected. Novo Nordisk's CagriSema showed up to 22.7% weight loss over 68 weeks in trials. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily.
Aug 07, 2025 • CNBC NEUTRAL
Eli Lilly's obesity pill led to more than 12% weight loss in closely watched late-stage trial, paving way for approval
Eli Lilly's pill, orforglipron, is one step closer to becoming the first new, needle-free alternative in the booming market for weight loss and diabetes drugs.
Jun 20, 2025 • Benzinga SOMEWHAT-BULLISH
Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671 - Structure Therapeutics ( NASDAQ:GPCR )
SAN FRANCISCO, June 20, 2025 ( GLOBE NEWSWIRE ) -- Structure Therapeutics Inc.
Jun 20, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671
SAN FRANCISCO, June 20, 2025 ( GLOBE NEWSWIRE ) -- Structure Therapeutics Inc. ( NASDAQ: GPCR ) , a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced two upcoming late-breaking poster presentations at the ...
Sentiment Snapshot

Average Sentiment Score:

0.205
50 articles with scored sentiment

Overall Sentiment:

Bullish

GPCR Reported Earnings

Mar 27, 2025
Dec 31, 2024 (Pre market)
-0.05 Surprise
  • Reported EPS: $-0.22
  • Estimate: $-0.17
  • Whisper: —
  • Surprise %: -32.3%
Nov 15, 2024
Sep 30, 2024 (Pre market)
-0.01 Surprise
  • Reported EPS: $-0.20
  • Estimate: $-0.19
  • Whisper: —
  • Surprise %: -7.1%
Aug 09, 2024
Jun 30, 2024 (Pre market)
0.04 Surprise
  • Reported EPS: $-0.18
  • Estimate: $-0.23
  • Whisper: —
  • Surprise %: 20.0%
May 09, 2024
Mar 31, 2024 (Post market)
0.02 Surprise
  • Reported EPS: $-0.19
  • Estimate: $-0.21
  • Whisper: —
  • Surprise %: 9.5%
Mar 08, 2024
Dec 31, 2023 (Pre market)
-0.32 Surprise
  • Reported EPS: $-0.53
  • Estimate: $-0.21
  • Whisper: —
  • Surprise %: -153.1%
Nov 14, 2023
Sep 30, 2023 (Post market)
-0.33 Surprise
  • Reported EPS: $-0.62
  • Estimate: $-0.29
  • Whisper: —
  • Surprise %: -113.8%
Aug 10, 2023
Jun 30, 2023 (Post market)
-0.32 Surprise
  • Reported EPS: $-0.60
  • Estimate: $-0.28
  • Whisper: —
  • Surprise %: -114.3%
May 11, 2023
Mar 31, 2023 (Post market)
0.16 Surprise
  • Reported EPS: $-0.25
  • Estimate: $-0.41
  • Whisper: —
  • Surprise %: 39.0%
Mar 31, 2023
Dec 31, 2022 (Post market)
-0.32 Surprise
  • Reported EPS: $-1.14
  • Estimate: $-0.82
  • Whisper: —
  • Surprise %: -39.0%

Financials